Evolus (EOLS) Scheduled to Post Quarterly Earnings on Wednesday

Evolus (NASDAQ:EOLS - Get Free Report) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Evolus to post earnings of ($0.08) per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.

Evolus (NASDAQ:EOLS - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analyst estimates of $65.06 million. On average, analysts expect Evolus to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Stock Performance

Shares of EOLS traded up $0.06 during trading hours on Wednesday, hitting $16.75. The company's stock had a trading volume of 469,300 shares, compared to its average volume of 581,178. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -15.95 and a beta of 1.31. The business has a 50 day simple moving average of $16.19 and a two-hundred day simple moving average of $13.63. Evolus has a 52-week low of $7.44 and a 52-week high of $17.82. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on EOLS shares. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, October 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Friday, September 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a research report on Monday, September 16th. Finally, Barclays raised their target price on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, September 13th.

Insider Transactions at Evolus

In other news, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares of the company's stock, valued at approximately $2,224,559.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company's stock, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.